Back to catalogue
№ 074 30 filings · 2021-09-03 → 2026-09-11

BERKELEY GROUP HOLDINGS (THE) PLC

BKG
Consumer Products and Services Share price 3,342p Market cap £3.0bn Overall fit 220 /1000

Well-run, asset-backed UK housebuilder trading modestly below NAV — but has essentially zero AI beneficiary exposure, only moderate operating leverage, and capacity-constrained by management design. Poor strategic fit for an AI-receiver / operating-leverage / valuation-discipline mandate despite decent standalone quality.

Fair value range 3,700p–4,200p Mid case · £3.6bn
Absolute upside +18.9% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Hard NAVPS of £39.17 at historic cost with £363m net cash
  • Well-documented, mature housebuilder valuation framework anchored on P/NAV
  • Management consistently meets (rebased) guidance and buys back stock below NAV
Limits the call
  • Timing of UK housing/rates/SDLT/planning recovery is genuinely uncertain
  • £6.4bn future gross margin is a management risk-adjusted estimate that moves with cycle
Methodology

Price-to-NAV cross-checked with normalised through-cycle P/E

In one line · bull case

Asset-backed UK housebuilder trading at 0.84× NAV with fortress balance sheet and accretive buy-backs below book, with optionality on UK planning/SDLT reform.

In one line · biggest risk

Continued deterioration in London sales rates and further regulatory/tax burden pushing realisation of the £6.4bn embedded land-bank margin out by years, forcing further guidance cuts and downward NAV revisions.

Drivers
AI beneficiary 5 /100
Pure UK residential developer; no meaningful direct or indirect AI value capture in filings.
Operating leverage 45 /100
FY26 revenue -4% drove operating margin 140bps lower and PBT -15%, so leverage exists but is modest and capacity is deliberately capped.
Earnings vs expectations 45 /100
Meets each guidance print but the guidance itself has been rebased down twice — managed-decline pattern, not beat pattern.
Growth momentum 25 /100
PBT down four years running; management guiding a further step-down and 25% production cut over four years.
Moat 45 /100
Land bank, brownfield/regeneration expertise and London focus provide narrow moat; ultimately competes on execution and planning ability.
Earnings quality 72 /100
Clean profits, strong cash conversion (£343m cash from ops FY26), high provisions for fire safety appropriately disclosed.
Management quality 75 /100
Long-tenured team, disciplined capital allocation, buys back below NAV, extremely candid disclosure and advocacy.
Cyclicality 80 /100
Housebuilder deeply tied to UK rates, SDLT, planning cycle and London prime market.
Leverage 12 /100
£363m net cash plus £1.4bn undrawn facilities; net cash / equity ~10%; fortress balance sheet.
Value-trap signals · 5
  • Four consecutive years of PBT decline (FY23 £604m → FY26 £451m)
  • Guidance rebased down twice (Dec 2023 extension; April 2026 -20%)
  • London housing starts <10% of MHCLG target — structural planning/regulatory drag
  • Sales reservations ~30% below FY23 run-rate for two years
  • Ordinary/special dividends effectively suspended in FY26, replaced by buy-backs

BKG — Berkeley Group Holdings PLC

Executive summary

Berkeley is a specialist UK residential developer focused almost exclusively on complex brownfield regeneration in London and the South-East, notable for its unrivalled land bank (52,700 plots, £6.4bn future gross margin), fortress balance sheet, and disciplined 10-year "Berkeley 2035" capital plan built around cash generation and share buy-backs. The operating trajectory across the period is one of clear deceleration — pre-tax profit has fallen from £604m (FY23) → £557m (FY24) → £529m (FY25) → £451m (FY26), with FY27 guidance implying a further step-down as management rebased to a "£1.4bn over four years" (£350m p.a.) plan on 1 April 2026 2026-04-01 strategy update; 2026-06-24 final results. The single most important valuation anchor is that at 3,294p the shares trade at ~0.84× the historic-cost NAVPS of £39.17 with net cash of £363m, and management is actively buying back stock below NAV — so downside is asset-backed, but there is no AI beneficiary angle whatsoever.

Fair value estimate

  • Fair value range: 3,700p – 4,200p (implied market cap £3,370m – £3,825m)
  • Methodology: primary — price-to-NAV benchmarked to housebuilder cross-cycle range (0.95–1.07× NAVPS of £39.17); cross-check — 10–12× normalised through-cycle earnings of ~£330–360m NPAT on £450–500m PBT.
  • Key assumptions: FY27 PBT ~£450m (management guidance implies ~£350m as a floor, but the 2035 plan targets 15% core ROCE which is closer to £450–500m PBT once cycle normalises); tax rate 29.5% (25% CT + 4% RPDT); ~91m shares outstanding falling on ongoing buy-back; NAVPS at cost understates market value of long-dated land holdings (£6.4bn future gross margin) but is offset by planning/regulatory risk.
  • Latest disclosed mcap: £3,150m; midpoint fair value ~£3,600m → absolute upside ~14%.
  • View: mildly undervalued on housebuilder fundamentals — but that has essentially nothing to do with the investor's thesis.

Sector context

  • Sector classification confirmed: Consumer Discretionary → Consumer Products and Services (Household Goods & Home Construction / Housebuilders). Berkeley is the UK-listed brownfield regeneration specialist, materially different from volume housebuilder peers.
  • Quality: above peers — fortress balance sheet (net cash £363m + £1.4bn undrawn facilities), AAA MSCI ESG rating, industry-leading NPS +77.9, +9% NAVPS growth in FY26 despite -15% PBT. Growth profile is below peers given deliberate 25% production cut announced April 2026. Leverage profile is materially better than peers.
  • Listed peers: Persimmon (PSN), Barratt Redrow (BTRW), Taylor Wimpey (TW.), Bellway (BWY), Vistry (VTY). Berkeley is uniquely exposed to London/prime South-East and BTR (Build to Rent), whereas peers are more suburban/first-time-buyer.

Investment thesis (3 bullets)

  1. Deep asset backing at a discount to NAV. Shares trade at 0.84× historic-cost NAVPS of £39.17, with £6.4bn future gross margin in land holdings and £1.0bn cash due on forward sales, providing hard downside protection 2026-06-24 final results.
  2. Aggressive, accretive buy-backs below NAV. Management is executing £640m of returns Oct-2025 → Sep-2030 predominantly via buy-backs while price < NAVPS; £171m already returned toward that target (£60m in first 4m of FY27 alone at £34.18/share) — every share retired accretes NAV/share 2026-09-11 trading update.
  3. Optionality on planning/SDLT reform and rate cuts. Berkeley has stopped acquiring new land and preserved its 52,700-plot bank; if government implements Homes for London package and/or reforms SDLT (Berkeley advocating cap at 1% for FTB/downsizers), currently un-viable consents could return to production and drive material uplift to future gross margin 2026-09-11 trading update; 2026-06-24 final results.

Key risks (3 bullets)

  1. Continued sales-rate softness and further guidance risk. Value of underlying sales reservations was -15% in FY26 vs prior year; management explicitly warned that Middle East conflict, UK political change and Budget uncertainty are causing buyers to defer 2026-09-11 trading update. FY27 profit guidance of "£1.4bn over 4 years" is a 20% cut vs the December 2024 profile.
  2. Planning and regulatory drag. Time from land acquisition to apartment completion in London has risen from 5 to 8+ years due to BSR/Gateway 2, Section 106, and pre-commencement conditions; Berkeley called out that London is delivering <10% of its housing target 2026-06-24 final results. RPDT (4%), corporation tax at 25%, and prospective Building Safety Levy compound this.
  3. Cyclical demand risk and value-adjustment risk in land bank. The £6.4bn future gross margin is management's risk-adjusted assessment; further deterioration in prices, planning outcomes, or build cost inflation could see plots transferred to pipeline (as ~5,500 were in FY23) or gross margin re-marked down. Housebuilders are structurally cyclical (not disclosed but inferred).

Operating leverage

Berkeley has moderate operating leverage but not the kind of asymmetric leverage this investor wants. FY26 revenue fell -4.2% while PBT fell -14.7% and operating margin compressed 140bps (20.1% → 18.7%), demonstrating that a substantial share of costs (land creditors' imputed interest, overhead of £150m, work-in-progress carrying costs) does not flex with revenue. Conversely, in a recovery, incremental sales at a stated ~25% gross margin against a £150m operating cost base (already reduced 25% in real terms over 3 years) would flow to profit at a high rate — a 10-20% revenue beat vs plan could plausibly add 25–40% to operating profit, but not multiples. However, the ceiling is capped by capacity — Berkeley has deliberately reduced production 25% over four years and paused new land investment, so upside surprise capacity is deliberately capped by the strategy 2026-04-01 strategy update. This is the opposite of a capacity-constrained business with pricing power that would translate demand surprise into profit multiples.

Value-trap signals

  • Sequential revenue and PBT declines four consecutive years (FY23 → FY26).
  • Repeated guidance rebases: FY24 aggregated with FY25 in 2023; extended 2 years in Dec-2024; rebased -20% in April 2026.
  • Structural planning/regulatory drag on London brownfield delivery with no near-term resolution — management explicitly says London is building "less than 10% of the homes it needs" 2026-06-24 final results.
  • Sales reservations run-rate ~30% below FY23 levels for two full years 2025-12-10 half-year report.
  • Special dividend eliminated in FY26 (2025: £183.8m special; 2026: £nil), replaced entirely by buy-backs — arguably a discipline, but a reduction in headline shareholder return.
  • Related-party transaction: sale of an apartment to CEO Rob Perrins approved at 2026 AGM (routine, disclosed, but noted).

Earnings vs. expectations

Across the period, Berkeley has been consistent about hitting the guidance it has set — but has repeatedly cut that guidance. FY23 (£604m PBT) and FY24 (£557m PBT) came in on/ahead of the guidance provided; FY25 delivered £529m vs the December 2024 guide of £525m; FY26 delivered £451m vs the June 2025 guide of £450m 2025-06-20 final results; 2026-06-24 final results. However, the underlying guidance path has been rebased downward twice — Dec 2023 extended a lower profile by 12 months, then April 2026 rebased FY27–FY30 down ~20% citing Middle East conflict and UK political uncertainty 2026-04-01 strategy update. Pattern: meets rebased guidance, but the base keeps stepping down — a classic managed-decline pattern in a cyclical business, not a serial beater.

Conviction

Conviction: 4 (high). Anchors: (1) audited hard-asset NAV of £39.17/share with net cash and a large, well-documented land bank provides a firm floor; (2) housebuilders are a well-covered sector with a mature price-to-NAV valuation framework; (3) management is disciplined and consistent, and buy-backs are executing below NAV. Limiting factors: (1) the timing of a UK housing recovery (rates, SDLT, planning) is genuinely uncertain and could push realisation of embedded margin out by years; (2) the future gross margin figure is a management estimate that has moved with the cycle.

Overall score rationale

This is a well-run, asset-backed, fortress-balance-sheet UK housebuilder trading below NAV — attractive for a value investor. It is completely misaligned with this specific investor's strategy: zero AI beneficiary exposure, moderate (not high) operating leverage, capacity-constrained by management choice, and cyclical rather than defensive. Score reflects poor strategic fit despite decent standalone fundamentals.

Filings consulted · 41

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-11Trading Statement2026-09-11_9766632_trading-statement.md0.85
  2. 2026-09-11Result OF Agm2026-09-11_9768524_result-of-agm.md0.30
  3. 2026-08-11Notice OF Agm2026-08-11_9716464_notice-of-agm.md0.30
  4. 2026-06-24Final Results2026-06-24_9633027_final-results.md1.00
  5. 2026-04-01Strategy And Trading Update2026-04-01_9501869_strategy-and-trading-update.md0.85
  6. 2026-03-13Trading Statement2026-03-13_9472460_trading-statement.md0.72
  7. 2025-12-10Half Year Financial Report2025-12-10_9286403_half-year-financial-report.md0.77
  8. 2025-09-05Trading Statement2025-09-05_9090058_trading-statement.md0.55
  9. 2025-09-05Result OF Agm2025-09-05_9091742_result-of-agm.md0.20
  10. 2025-08-04Notice OF Agm2025-08-04_9026165_notice-of-agm.md0.20
  11. 2025-06-20Final Results2025-06-20_8939419_final-results.md0.65
  12. 2025-03-14Trading Statement2025-03-14_8779015_trading-statement.md0.55
  13. 2025-02-27Dividend Declaration2025-02-27_8755686_dividend-declaration.md0.20
  14. 2024-12-06Half Year Report2024-12-06_8594063_half-year-report.md0.58
  15. 2024-09-06Trading Statement2024-09-06_8402963_trading-statement.md0.38
  16. 2024-09-06Result OF Agm2024-09-06_8404756_result-of-agm.md0.14
  17. 2024-08-02Notice OF Agm2024-08-02_8347534_notice-of-agm.md0.14
  18. 2024-06-19Revision TO Dividend Declaration2024-06-19_8268388_revision-to-dividend-declaration.md0.14
  19. 2024-06-19Final Results2024-06-19_8266504_final-results.md0.45
  20. 2024-03-15Trading Statement2024-03-15_8089280_trading-statement.md0.38
  21. 2024-03-01Revision TO Dividend Declaration2024-03-01_8064983_revision-to-dividend-declaration.md0.14
  22. 2024-02-29Dividend Declaration2024-02-29_8062252_dividend-declaration.md0.14
  23. 2023-12-08Half Year Report2023-12-08_7929679_half-year-report.md0.41
  24. 2023-09-08Trading Statement2023-09-08_7743009_trading-statement.md0.21
  25. 2023-09-08Result OF Agm2023-09-08_7744660_result-of-agm.md0.07
  26. 2023-08-10Dividend Declaration2023-08-10_7687247_dividend-declaration.md0.07
  27. 2023-08-07Notice OF Agm2023-08-07_7681042_notice-of-agm.md0.07
  28. 2023-06-21Final Results2023-06-21_7584917_final-results.md0.25
  29. 2023-03-10Trading Statement2023-03-10_7392733_trading-statement.md0.21
  30. 2023-02-23Dividend Declaration2023-02-23_7505026_dividend-declaration.md0.07
  31. 2022-12-09Half Year Report2022-12-09_7361015_half-year-report.md0.23
  32. 2022-09-06Trading Statement2022-09-06_7211543_trading-statement.md0.21
  33. 2022-09-06Result OF Agm2022-09-06_7212962_result-of-agm.md0.07
  34. 2022-08-11Dividend Declaration2022-08-11_7060467_dividend-declaration.md0.07
  35. 2022-08-03Notice OF Agm And Annual Report2022-08-03_7008242_notice-of-agm-and-annual-report.md0.24
  36. 2022-06-22Final Results2022-06-22_7023599_final-results.md0.25
  37. 2022-03-15Acquisition2022-03-15_6899986_acquisition.md0.19
  38. 2022-03-11Trading Statement2022-03-11_6894717_trading-statement.md0.21
  39. 2021-12-08Half Year Report2021-12-08_6756104_half-year-report.md0.23
  40. 2021-09-03Result OF Agm2021-09-03_6719325_result-of-agm.md0.03
  41. 2021-09-03Agm Statement2021-09-03_6718133_agm-statement.md0.04

This research note was authored by a large language model after reading 30 regulatory filings published between 2021-09-03 and 2026-09-11. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.